Quarterly ResultJun 29, 2026, 07:40 AM
Helus Pharma Reports FY26 Results; HLP003 Phase 3 88% Enrolled; $50M Offering
AI Summary
Helus Pharma reported audited financial results for its fiscal year ended March 31, 2026, with a net loss of $148.0 million, an increase from the prior year, driven by advanced clinical trials. The company recently closed a $50 million underwritten offering, bolstering its balance sheet. Key business highlights include HLP003 Phase 3 APPROACH study surpassing 88% enrollment, with topline data anticipated in Q4 2026, and positive Phase 2 results for HLP004 in Generalized Anxiety Disorder.
Key Highlights
- Closed $50 million underwritten offering.
- HLP003 Phase 3 APPROACH study over 88% enrolled; topline data expected Q4 2026.
- HLP003 Phase 2 data showed 100% response and 71% remission at 12 months.
- HLP004 Phase 2 showed ~10-point HAM-A improvement in GAD.
- Cash totaled $157.3 million as of March 31, 2026.
- Net loss for fiscal year 2026 was $148.0 million.
- Cash-based operating expenses for fiscal year 2026 were $131.7 million.
- Strengthened scientific and medical leadership with new appointments.
Price Impact
More from HELP